In the last trading session, 1.59 million shares of the AbCellera Biologics Inc (NASDAQ:ABCL) were traded, and its beta was 0.39. Most recently the company’s share price was $3.97, and it changed around -$0.04 or -1.00% from the last close, which brings the market valuation of the company to $1.16B. ABCL currently trades at a discount to its 52-week high of $8.05, offering almost -102.77% off that amount. The share price’s 52-week low was $3.79, which indicates that the current value has risen by an impressive 4.53% since then. We note from AbCellera Biologics Inc’s average daily trading volume that its 3-month average coming to 1.32 million.

AbCellera Biologics Inc (NASDAQ:ABCL) trade information

Instantly ABCL has showed a red trend with a performance of -1.00% at the end of last trading. The performance over the last five days has remained in the red territory. The company’s shares are currently down -30.47% year-to-date, but still down -1.98% over the last five days. On the other hand, AbCellera Biologics Inc (NASDAQ:ABCL) is -13.51% down in the 30-day period.

The consensus price target as assigned by Wall Street analysts is $27.75, which translates to bulls needing to increase their stock price by 85.69% from its current value. Analyst projections state that ABCL is forecast to be at a low of $18 and a high of $34.

AbCellera Biologics Inc (ABCL) estimates and forecasts

AbCellera Biologics Inc share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -8.10 percent over the past six months and at a -29.41% annual growth rate that is well below the industry average of 13.00%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will loss -14.30% in revenue this quarter, and will report a decrease of -36.40% in the next quarter. The year-over-year growth rate is expected to be 25.80%, up from the previous year.

Consensus estimates provided by 8 financial analysts predict the company will bring in an average of $11.02 million in revenue for the current quarter. 8 analysts expect AbCellera Biologics Inc to make $11.53 million in revenue for the quarter ending Jun 2024. The company’s sales for the same quarters a year ago were $12.19 million and $10.06 million respectively. Analysts predict that the company’s current quarter sales will drop, forecast at -9.60%. Forecasts for the next quarter put sales growth at 14.70%.

AbCellera Biologics Inc earnings are expected to increase by 4.48% in 2024, but the outlook is positive 10.00% per year for the next five years.

ABCL Dividends

AbCellera Biologics Inc’s next quarterly earnings report is expected to be released in May.